首页> 外文会议>Current Trends in Information Technology (CTIT), 2009 >A new method for measuring Auto-Fluorescence changes in neovascular-AMD after intravitreal injection of Bavecizumab
【24h】

A new method for measuring Auto-Fluorescence changes in neovascular-AMD after intravitreal injection of Bavecizumab

机译:玻璃体腔内注射Bavecizumab后测量新生血管AMD自发荧光变化的新方法

获取原文

摘要

Age-related macular degeneration (AMD) is the second disease diabetes which causes blindness in aged people. The only remedy for AMD is intravenous injection of Bavecizumab. To prove the efficiency of remedy, the degenerated cells in macula should be measured. In this paper, the new software is introduced to measure auto-fluorescence in macula part of retina in order to determine the number of degenerated cells. This system is consists of three main parts: low level pre-processing, image analysis and images understanding. Experiments have been done on a database of 34 retina images of before and after AMD patients remedy. The average number of decreased degenerated cells after remedy was 15134. In clinical reviews, the founded relation to disinflation of macula has been proved, while there were no proved relations to the vision decreasing or increasing of patients.
机译:年龄相关性黄斑变性(AMD)是第二种导致老年人失明的疾病。 AMD的唯一​​治疗方法是静脉注射Bavecizumab。为了证明治疗的有效性,应该测量黄斑中退化的细胞。在本文中,引入了新的软件来测量视网膜黄斑部分的自发荧光,以确定变性细胞的数量。该系统包括三个主要部分:低级预处理,图像分析和图像理解。已经在AMD患者治疗前后的34张视网膜图像的数据库上进行了实验。补救后退化细胞的平均数量为15134。在临床评价中,已证实与黄斑去充气有关的既定关系,而与患者视力下降或增加没有关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号